Preparing and submitting an Abbreviated New Drug Application (ANDA) requires a comprehensive understanding of FDA regulatory requirements, pharmaceutical development, and the scientific documentation necessary to demonstrate the quality and equivalence of a proposed generic drug product. Incomplete applications, inconsistent technical information, and unresolved regulatory considerations can result in costly delays and additional review cycles.
PD Partners has extensive experience directly preparing and submitting ANDAs to the FDA, providing clients with the regulatory expertise needed to navigate this complex process. Our team understands the importance of coordinating pharmaceutical development activities with regulatory expectations, ensuring that critical technical information is appropriately documented, reviewed, and incorporated into the application.
From initial regulatory strategy and application planning through submission preparation and FDA review support, we work closely with clients to identify potential deficiencies, address regulatory challenges, and prepare comprehensive applications that support an efficient review process.
How It Works
Successful ANDA preparation begins well before an application is submitted. Establishing an appropriate regulatory pathway, identifying the Reference Listed Drug (RLD), and understanding applicable FDA requirements are essential to developing a comprehensive submission strategy.
PD Partners coordinates the preparation and compilation of regulatory documentation, including:
- Regulatory Strategy & Application Planning — Evaluate the proposed product, applicable requirements, and submission objectives.
- Chemistry, Manufacturing & Controls (CMC) — Prepare and review documentation addressing drug substance, drug product, manufacturing processes, specifications, and quality controls.
- Analytical & Validation Documentation — Compile analytical procedures, validation reports, and supporting product quality data.
- Stability Data & Shelf-Life Justification — Organize stability information supporting proposed storage conditions and expiration dating.
- Bioequivalence Documentation — Coordinate the incorporation of applicable bioequivalence studies, supporting data, and related regulatory information.
- Product Labeling — Evaluate proposed labeling against applicable FDA requirements and reference product information.
- Electronic Regulatory Submissions — Prepare, compile, and submit applications in the FDA-required electronic Common Technical Document (eCTD) format.
Our approach emphasizes consistency across application sections, technical accuracy, and careful documentation to help minimize avoidable deficiencies during FDA review.
Our ANDA Preparation & Submission Process
1. Regulatory Assessment
Evaluate the proposed drug product, reference listed drug, applicable FDA requirements, and regulatory pathway to establish an appropriate submission strategy.
2. Application Planning
Identify required studies, technical documentation, regulatory milestones, and potential gaps that must be addressed before submission.
3. Technical Documentation Review
Evaluate pharmaceutical development, manufacturing, analytical, stability, and bioequivalence information for completeness and consistency.
4. Application Preparation
Compile the required regulatory documentation, technical reports, product specifications, and supporting information into the appropriate ANDA sections.
5. Labeling & Regulatory Review
Assess proposed labeling and application content for consistency with applicable FDA requirements and the reference listed drug.
6. Electronic Submission
Assemble, validate, and submit the completed ANDA using the applicable FDA electronic submission requirements.
7. FDA Review Support
Assist clients in addressing FDA information requests, review comments, and application deficiencies throughout the regulatory review process.
Benefits of Working with PD Partners
- Extensive direct experience preparing and submitting ANDAs to the FDA
- Comprehensive understanding of pharmaceutical regulatory requirements
- Early identification of potential submission deficiencies and documentation gaps
- Coordinated preparation of CMC, analytical, stability, and supporting regulatory documentation
- Experience with FDA electronic submission requirements and application organization
- Practical regulatory guidance throughout application preparation and review
- Integrated scientific and regulatory expertise supporting efficient project execution
Our Commitment to Regulatory Excellence
PD Partners recognizes that the quality of a regulatory submission depends on the accuracy, completeness, and consistency of the scientific information supporting it. Our approach emphasizes careful technical review, thorough documentation, and proactive identification of potential regulatory concerns.
By applying our experience in pharmaceutical development and FDA submissions, we help clients prepare well organized applications that address applicable regulatory expectations and support informed FDA review.